Top

Supportive Care in Cancer

Published in:

01-07-2011 | Original Article

Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study

Authors: Heather McKenzie, Lillian Hayes, Kathryn White, Keith Cox, Judith Fethney, Maureen Boughton, Jo Dunn

Published in: Supportive Care in Cancer | Issue 7/2011

Abstract

Goal of work

This descriptive, retrospective study sought to identify the nature and magnitude of chemotherapy outpatients’ unplanned presentations and admissions to the emergency department and/or cancer centre at a large metropolitan tertiary hospital, and to explore the antecedents to those presentations.

Patients and methods

Retrospective data were collected for outpatients who made an unplanned presentation to a large metropolitan hospital in Sydney, Australia between October 1, 2006 and September 30, 2007. Detailed information was collected for those who had received cytotoxic chemotherapy at the hospital’s cancer centre within the 6 months prior to the unplanned presentation to hospital. Demographic and explanatory variables were identified, including: reasons for presentation, cancer diagnosis, chemotherapy regimens, and position in the chemotherapy trajectory.

Main results

The Cancer Institute NSW [27] figures indicate that each year approximately 518 outpatients are treated with chemotherapy at the participating cancer centre. During the study period, 316 cancer outpatients made 469 unplanned presentations to either the Cancer Centre or the hospital emergency department. Of those outpatients presented, 233 (73.7%) had received chemotherapy in the previous 6 months and made a total of 363 presentations. Of these 363 presentations, 253 (69.7%) occurred within 4 weeks of receiving chemotherapy. The majority of presentations by those who had received chemotherapy in the previous 6 months resulted in hospital admission (87.6%) for a median length of stay of 5 days. The most frequent presentation symptoms were nausea and/or vomiting (45.2%), pain (27%), fever and/or febrile neutropenia (23.4%), shortness of breath (19.3%), dehydration (12.1%), anaemia (8.8%), fatigue (8.8%), diarrhoea (8.8%), and anxiety and/or depression (5.5%).

Conclusions

Chemotherapy outpatients have significant unmet needs following treatment, indicating an urgent need for improved continuity of care and better integration of primary and tertiary health care services.

Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natol Cancer Inst 98(16):1108–1117CrossRef

National Health & Medical Research Council (NHMRC) (2003) Clinical practice guidelines for the psychosocial care of adults with cancer. National Breast Cancer Centre, Camperdown

Australian Institute of Health and Welfare (AIHW) (2008) Australian hospital statistics 2006-07, health services series no. 31. Cat. No. HSE 55, Canberra

Australian Institute of Health and Welfare (AIHW) (2007) Cancer in Australia: an overview, 2006, AIHW Cancer series no. 37. Cat. no. CAN 32, Canberra

Otto S (2001) Chemotherapy. In: Otto S (ed) Oncology nursing, 4th edn. Mosby, Sydney, p 638

Cooper C, Depledge J (2004) Cytotoxic chemotherapy: what do community nurses need to know? Br J Community Nurs 9(1):26–32PubMed

Jefford M, Baravelli C, Dudgeon P, Dabscheck A, Evans M, Moloney M, Scholfield P (2008) Tailored chemotherapy information faxed to General Practitioners improves confidence in managing adverse effects and satisfaction with shared care: results from a randomised controlled trial. J Clin Oncol 26(14):2272–2277PubMedCrossRef

National Health and Hospitals Reform Commission (NHHRC) (2008) A healthier future for all Australians: interim report of the national health and hospitals reform commission. National Health and Hospitals Reform Commission, Canberra

Mitchell T (2007) The social and emotional toll of chemotherapy – patients’ perspectives. Eur J Cancer Care 16:39–44CrossRef

10.

Read H, Ladds S, Rhodes B, Brown D, Portlock J (2007) The Impact of a supplementary medication review and counseling service within the oncology outpatient setting. B J Cancer 96:744–75CrossRef

11.

Grunber SM, Dueson RR, Marros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics; perception versus reality. Cancer 100(10):2261–2268CrossRef

12.

Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunber S, Koeller J, Olver I, Borjeson S, Ballatori E (2004) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy, Support Care Cancer [Online] 13(2) Available: http://dx.doi.org/10.1007/s00520-004-0699-x

13.

Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manag 20(2):113–121CrossRef

14.

Apro M, Blower P (2005) 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administrative agents? Cancer 104(1):1–13CrossRef

15.

Pronzab P (2006) Cancer-related anaemia management in the 21st Century. Cancer Treat Rev 32:S1–S3CrossRef

16.

Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncol 5:353–360CrossRef

17.

Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing Patient Perceptions of the Side Effects of Cancer Chemotherapy. Cancer 95(1):155–163PubMedCrossRef

18.

Barsevick AM, Dudley W, Beck S, Sweeney C, Whitmer K, Nail L (2004) A randomised clinical trial of energy conservation for patients with cancer-related fatigue. Cancer 15(100):1302–1310CrossRef

19.

Deandrea S, Montanari M, Moja L, Apolone G (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. doi:10.1093/annonc/mdn419

20.

Schumacher KL, Koresawa S, West C, Hawkins C, Johnson C, Wais E, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C (2002) Putting cancer pain management regimens into practice at home. J Pain Symptom Manag 23(5):369–382CrossRef

21.

Fortner BV, Ashley J, Chavez J (2003) Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manag 25(1):9–18CrossRef

22.

Chrisholm JC, Drommett D (2006) The evolution towards ambulatory and day-case management of febrile neutropenia. Br J Haematol 135:3–16CrossRef

23.

Padilla G, Ropka ME (2005) Quality of life and chemotherapy-induced neutropenia. Cancer Nurs 28(3):167–171PubMedCrossRef

24.

Sipas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103–1113CrossRef

25.

Innes HE, Smith DB, O’Reilly SM, Clark PL, Kelly V, Marshall E (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study. Br J Cancer 89(1):43–49PubMedCrossRef

26.

Commonwealth Department of Health and Aging (2007) National Hospital Cost Data Collection: Cost Report Round 10 (2005-2006) AR-DRGv5.0, Commonwealth Department of Health and Aging, Canberra

27.

Cancer Institute NSW (CINSW) (2006) Review of ambulatory/outpatient chemotherapy and haematology services in New South Wales 2005, Health Technology Analysts, NSW

28.

McKenzie H, Boughton M, Hayes L, Forsyth S, Davies M, Underwood E et al (2007) A sense of security for cancer patients at home: the role of community nurses. Health Soc Care Community 15(4):352–9PubMedCrossRef

29.

Cancer Institute NSW (CINSW) (2007) A survey of Multidisciplinary Teams in New South Wales, Sydney

30.

Cancer Nurses Society of Australia (CNSA) (2008) Position Statement for cancer coordinators, CNSA

31.

Health V (2008) Linking cancer care: a guide for implementing coordinated cancer care. Metropolitan Health and Aged Care Services Division, Melbourne

32.

McKenzie H, Hayes L, Forsyth S (2008) Explaining the complexities and value of nursing practice and knowledge. In: Crouch M, Morley I (eds) Illumination through critical prisms. Rodopi, Amsterdam

33.

Molassiotis A, Brearley S, Saunders M, Craven O, Wardley A, Farrell C, Swindell R, Todd C, Luker K (2009) Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol 27:6191–6198PubMedCrossRef

34.

McKenzie H, Boughton M, Hayes L, Forsyth S (2007) Struggling to articulate the value of its knowledge base: the crisis in contemporary nursing. In: Morley I (ed) The value of knowledge e-book. Inter-Disciplinary Press, Oxford

35.

Smith J (2002) The changing face of community and district nursing. Aust Health Rev 25(3):131–133PubMedCrossRef

36.

Moore K, Johnson G, Fortner BV, Houts AC, Moore K, Johnson G, Fortner BV, Houts AC (2008) The AIM Higher Initiative: new procedures implemented for assessment, information, and management of chemotherapy toxicities in community oncology clinics. Clin J Oncol Nurs 12(2):229–38PubMedCrossRef

37.

Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Tittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manag 34(2):148–158CrossRef

Title: Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study
Authors: Heather McKenzie
Lillian Hayes
Kathryn White
Keith Cox
Judith Fethney
Maureen Boughton
Jo Dunn
Publication date: 01-07-2011
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 7/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-010-0913-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Goal of work

Patients and methods

Main results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2011

ShopTalk: a pilot study of the feasibility and utility of a therapeutic board game for youth living with cancer

Erratum to: Dying with dignity according to Swedish medical students

Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice

Sleep in children with cancer: case review of 70 children evaluated in a comprehensive pediatric sleep center

Behavioral risk factors and use of preventive screening services among spousal caregivers of cancer patients

Cancer-related psychosocial research: what are the perspectives of cancer care centre users on participation?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer